Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F22%3A00013717" target="_blank" >RIV/00023736:_____/22:00013717 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/22:00128761 RIV/65269705:_____/22:00077804 RIV/00098892:_____/22:10157777
Result on the web
<a href="https://doi.org/10.1182/blood.2022017257" target="_blank" >https://doi.org/10.1182/blood.2022017257</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/blood.2022017257" target="_blank" >10.1182/blood.2022017257</a>

Result language
angličtina
Original language name
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Original language description
Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)